WALTHAM, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today reported publication of results from a randomized controlled trial of Quell ® in subjects with chronic low back ...
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Quell ® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American ...
Neurometrix has received FDA clearance for a new smartphone-controlled version of Quell, its wearable for pain relief, the company announced last week. Like its predecessor, the device will use nerve ...
WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a ...
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an ...
Earnings reports shared by neurostimulation and digital medicine company NeuroMetrix during a Q2 investors’ call showed a slight drop in total revenue as the company is preparing to place its ...
Living with chronic pain can be debilitating. Routine medications are common in pain management, but they often come with their own side effects. Opioid addiction is a significant public health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results